In a recent interview with Health Biz Insight, Mr. Sanjeev Vashishta, MD & CEO of PathKind Diagnostics threw some light on PathKind’s unique strategy of targeting North India’s tier 2, 3 & 4 locations before moving to the bigger cities.
He stated that PathKind intends to invest a little over Rs. 400 crore in the diagnostics business, and is aiming to bring standardization across all their centers in terms of systems, processes, and operating protocols. Providing the people of India access to meaningful technologies and tests, which are specific, sensitive, and affordable at the same time, were some of the key highlights of his conversation.
When asked about the future business plans in the end, Mr. Vashishta said that PathKind is looking to have a pan-India presence in the next 5 years, and planning to turn their EBIDTA positive in the 5th year.